The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia

Pharmacology Biochemistry and Behavior

Volumn 78, Issue 4, 2004, Pages 805-810

  Malik, Peter ^a   Andersen, Maibritt B ^a   Peacock, Linda ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Dopamine D1 agonist; Dopamine D3 agonist; Dopamine D3 antagonist; Monkey; Tardive dyskinesia

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; BENZ[E]INDOLE 8 HYDROXY 3 (N PROPYL) 1,2,3A,4,5,9B HEXAHYDRO 1H BENZ[E]INDOLE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; INDOLE DERIVATIVE; PRAMIPEXOLE; SB 27701A; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; DISEASE SEVERITY; DRUG EXPOSURE; DYSKINESIA; FEMALE; MALE; MONKEY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

ANIMALS; BENZAZEPINES; BENZOTHIAZOLES; CEBUS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; INDOLES; MALE; NITRILES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDROISOQUINOLINES; THIAZOLES;

CEBUS; PRIMATES;

EID: 3843095046     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2004.05.019     Document Type: Article

References (26)

1. 2A receptor agonist CGS 21680 exhibits antipsychotic-like activity in Cebus apella monkeys. Behav. Pharmacol. 13:2002;639-644
2. 4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology. 28:2003;1168-1175
3. Austin N.E., Baldwin S.J., Cutler L., Deeks N., Kelly P.J., Nash M., et al. Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica. 31:2001;677-686
4. Brotchie J.M., Fox S.H. Quantitative assessment of dyskinesias in subhuman primates. Mov. Disord. 14(Suppl. 1):1999;40-47
5. Cadet J.L., Lohr J.B. Possible involvement of free radicals in neuroleptic-induced movement disorders - evidence from treatment of tardive dyskinesia with vitamin E. Ann. N. Y. Acad. Sci. 570:1989;178-185
6. Eichhammer P., Albus M., Borrmann-Hassenbach M., Schoeler A., Putzhammer A., Frick U., et al. Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am. J. Med. Genet. 96:2000;187-191
7. Fibiger H.C., Lloyd K.G. Neurobiological substrates of tardive dyskinesia - the GABA hypothesis. Trends Neurosci. 7:1984;462-464
8. Fink-Jensen A., Nielsen E.B., Hansen L., Scheideler M.A. Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist CIS-8-OH-PBZI. Eur. J. Pharmacol. 342:1998;153-161
9. Gerlach J. Relationship between tardive dyskinesia, L-Dopa-induced hyperkinesia and parkinsonism. Psychopharmacology. 51:1977;259-263
10. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiatr. Scand. 77:1988;369-378
11. Gerlach J., Hansen L. Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D1-D2 supersensitivity. J. Psychopharmacol. 7:1993;355-364
12. Joyce J.N. Dopamine D-3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90:2001;231-259
13. Klawans H.L., Goetz C.G., Perlik S. Tardive-dyskinesia - review and update. Am. J. Psychiatry. 137:1980;900-908
14. Lublin H. Dopamine receptor agonist- and antagonist-induced behaviors in primates previously treated with dopamine receptor antagonists: the pathogenetic mechanisms of acute oral dyskinesia. Clin. Neuropharmacol. 18:1995;533-551
15. Lublin H., Gerlach J. Behavioral effects of dopamine D-1 and D-2 receptor agonists in monkeys previously treated with haloperidol. Eur. J. Pharmacol. 153:1988;239-245
16. Mierau J., Schneider F.J., Ensinger H.A., Chio C.L., Lajiness M.E., Huff R.M. Pramipexole binding and activation of cloned and expressed dopamine D-2, D-3 and D-4 receptors. Eur. J. Pharmacol., Mol. Pharmacol. 290:1995;29-36
17. Peacock L., Gerlach J. Effects of several partial dopamine D2 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur. J. Pharmacol. 237:1993;329-340
18. Peacock L., Gerlach J. A reanalysis of the dopamine theory of tardive dyskinesia: the D1/D2 imbalance hypothesis. Yassa R., Nair N.P.V., Jeste D. Neuroleptic-induced movement disorders. 1997;141-160 Cambridge University, Cambridge
19. Peacock L., Gerlach J. New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects. Psychopharmacology. 144:1999;189-197
20. Peacock L., Lublin H., Gerlach J. The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur. J. Pharmacol. 186:1990;49-59
21. Reavill C., Taylor S.G., Wood M.D., Ashmeade T., Austin N.E., Avenell K.Y., et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D-3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294:2000;1154-1165
22. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesias in naive rats by D1-stimulation. Life Sci. 33:1983;2479-2482
23. Scheideler M.A., Martin J., Hohlweg R., Rasmussen J.S., Naerum L., Ludvigsen T.S., et al. The preferential dopamine D3 receptor agonist CIS-8-OH-PBZI induces limbic Fos expression in rat brain. Eur. J. Pharmacol. 339:1997;261-270
24. Sibley D.R., Monsma F.J. Jr., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 35:1993;391-415. [Review]
25. Steen V.M., Lovlie R., MacEwan T., McCreadie R.G. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry. 2:1997;139-145
26. Witkin J., Gasior M., Acri J., Beekman M., Thurkauf A., Yuan J., et al. Atypical antipsychotic-like effects of the dopamine D3 receptor agonist, (+)-PD 128,907. Eur. J. Pharmacol. 347:1998;R1-R3